• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Blissgvs Share Price

    Bliss Gvs Pharma Share PriceBliss GVS Pharma

    Small Cap 4.3k Result
    ₹91.8
    0.4 (0.44%)
    As on 22 September, 2023 | 08:20 BSE: 506197 NSE: BLISSGVSISIN: INE416D01022

    Bliss Gvs Pharma Performance

    Day Range

    • Low 91
    • High 92.95
    91.8

    52 Week Range

    • Low 69.2
    • High 104
    91.8
    • Open Price91.5
    • Previous Close91.4
    • Volume161793

    Start SIP in Bliss GVS Pharma

    Start SIP

    Bliss Gvs Pharma Share Price

    • Over 1 Month -0.43%
    • Over 3 Month 11.41%
    • Over 6 Month 22.07%
    • Over 1 Year 11.81%

    Bliss Gvs Pharma Key Statistics

    P/E Ratio 16
    PEG Ratio 0.1
    Market Cap Cr 958
    Price to Book Ratio 1
    EPS 8.2
    Dividend 0.5
    Relative Strength Index 43.99
    Money Flow Index 28.5
    MACD Signal 0.31
    Average True Range 3.74

    Bliss Gvs Pharma Investment Rating

    • Master Rating:

    • Bliss Gvs Pharma has an operating revenue of Rs. 722.45 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 14% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 5%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 14% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 11% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 15 which is a POOR score indicating inconsistency in earnings, a RS Rating of 55 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 81 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Bliss GVS Pharma Financials
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 109143169139147138
    Operating Expenses Qtr Cr 98133135112128129
    Operating Profit Qtr Cr 11113327199
    Depreciation Qtr Cr 544443
    Interest Qtr Cr 151222
    Tax Qtr Cr 32111077
    Net Profit Qtr Cr 762925259
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 649669
    Operating Expenses Annual Cr 508527
    Operating Profit Annual in Cr 90109
    Depreciation Cr 1514
    Interest Annual Cr 104
    Tax Annual Cr 3034
    Net Profit Annual Cr 8593
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 44114
    Cash from Investing Activity Annual Cr -13-92
    Cash from Financing Annual Activity Cr -26-13
    Net Cash Flow Annual Cr 59
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 937851
    Fixed Assets Annual Cr 328247
    Total Non Current Assets Annual Cr 410289
    Total Current Assets Annual Cr 730791
    Total Assets Annual Cr 1,1401,080
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 9082
    ROE Annual % 911
    ROCE Annual % 1314
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2422
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 160185206172189167
    Operating Expenses Qtr Cr 135179158148150147
    Operating Profit Qtr Cr 24648253920
    Depreciation Qtr Cr 655554
    Interest Qtr Cr 151222
    Tax Qtr Cr 7-4184123
    Net Profit Qtr Cr 15328142620
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 769779
    Operating Expenses Annual Cr 634629
    Operating Profit Annual in Cr 117118
    Depreciation Cr 1917
    Interest Annual Cr 105
    Tax Annual Cr 2931
    Net Profit Annual Cr 7115
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 34135
    Cash from Investing Activity Annual Cr -8-93
    Cash from Financing Annual Activity Cr -25-24
    Net Cash Flow Annual Cr 219
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 884819
    Fixed Assets Annual Cr 374296
    Total Non Current Assets Annual Cr 459333
    Total Current Assets Annual Cr 697776
    Total Assets Annual Cr 1,1571,109
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 8882
    ROE Annual % 82
    ROCE Annual % 1215
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1820

    Bliss Gvs Pharma Technicals

    EMA & SMA

    Current Price
    ₹91.8
    0.4 (0.44%)
    • Bullish Moving Average
    • ___
    • 5
    • Bearish Moving Average
    • ___
    • 11
    • 20 Day
    • ₹94.31
    • 50 Day
    • ₹92.48
    • 100 Day
    • ₹88.17
    • 200 Day
    • ₹84.13
    • 20 Day
    • ₹95.58
    • 50 Day
    • ₹94.96
    • 100 Day
    • ₹85.93
    • 200 Day
    • ₹80.27

    Bliss Gvs Pharma Resistance and Support

    PIVOT
    ₹91.92
    Resistance
    First Resistance ₹92.84
    Second Resistance ₹93.87
    Third Resistance ₹94.79
    RSI 43.99
    MFI 28.5
    MACD Single Line 0.31
    MACD -0.36
    Support
    First Resistance ₹90.89
    Second Resistance ₹89.97
    Third Resistance ₹88.94

    Bliss Gvs Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 189,061 8,991,741 47.56
    Week 235,443 13,549,716 57.55
    1 Month 349,194 16,618,163 47.59
    6 Month 334,786 16,679,057 49.82

    Bliss Gvs Pharma Result Highlights

    Bliss GVS Pharma Synopsis

    NSE-Medical-Generic Drugs

    Bliss Gvs Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 598.34 Cr. and Equity Capital is Rs. 10.42 Cr. for the Year ended 31/03/2023. Bliss GVS Pharma Ltd. is a Public Limited Listed company incorporated on 11/12/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1984PLC034771 and registration number is 034771.
    Market Cap 958
    Sales 560
    Shares in Float 6.79
    No of funds 24
    Yield 0.54
    Book Value 1.02
    U/D Vol ratio 2
    LTDebt / Equity 4
    Alpha 0.04
    Beta 0.56

    Bliss GVS Pharma

    Owner NameJun-23Mar-23Dec-22Sep-22
    Promoters 35.12%35.04%34.46%34.55%
    Mutual Funds
    Insurance Companies 6.62%6.63%6.63%6.64%
    Foreign Portfolio Investors 16.5%16.6%16.53%16.68%
    Individual Investors 30.1%30.01%30.73%30.57%
    Others 11.66%11.72%11.65%11.56%

    Bliss GVS Pharma Management

    Name Designation
    Mr. S R Vaidya Chairman & Ind.Director
    Mr. Gagan Harsh Sharma Managing Director
    Dr. Vibha Gagan Sharma Whole Time Director
    Mrs. Shruti Vishal Rao Whole Time Director
    Mr. Santosh L Parab Independent Director
    Mrs. Shilpa Bhatia Independent Woman Director

    Bliss Gvs Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Bliss Gvs Pharma Corporate Action

    Date Purpose Remarks
    2023-08-01 Quarterly Results
    2023-05-11 Audited Results & Final Dividend
    2023-01-24 Quarterly Results
    2022-11-07 Quarterly Results
    2022-08-03 Quarterly Results

    Bliss GVS Pharma MF Shareholding

    Name Amount(cr)
    Motilal Oswal S&P BSE Healthcare ETF 8
    • Company Name
    • CMP
    • Chg(%)
    • Company Name
    • CMP
    • Chg(%)

    Bliss GVS Pharma FAQs

    What is Share Price of Bliss GVS Pharma ?

    Bliss GVS Pharma share price is ₹91 As on 22 September, 2023 | 08:06

    What is the Market Cap of Bliss GVS Pharma ?

    The Market Cap of Bliss GVS Pharma is ₹958.4 Cr As on 22 September, 2023 | 08:06

    What is the P/E ratio of Bliss GVS Pharma ?

    The P/E ratio of Bliss GVS Pharma is 16 As on 22 September, 2023 | 08:06

    What is the PB ratio of Bliss GVS Pharma ?

    The PB ratio of Bliss GVS Pharma is 1 As on 22 September, 2023 | 08:06

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Enter Mobile Number

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.